Single-Institution Experience of Larotrectinib Therapy for Patients With NTRK Fusion-Positive Thyroid Carcinoma.
Omar ElghawyAdam BarsoukAlec HeidlaufSimon ChenRoger B CohenLova L SunPublished in: Journal of the Endocrine Society (2024)
inhibition led to an mPFS of 25 months, with survival surpassing historic benchmarks for ATC and PDTC.
Keyphrases